Patients with severe hemophilia A who have developed factor VIII inhibitors cannot achieve adequate haemostasis through standard FVIII replacement. When these patients present with acute joint bleeding, an alternative bypassing strategy is required to control the bleed and protect joint integrity.
Current guideline recommendations support recombinant FVIIa (eptacog alfa) as the bypassing agent in this setting. The specific dosing regimen — including how doses are structured and timed — is detailed in the full evidence-based protocol.
Complete dosing schedule, evidence grading, and clinical decision points are available in the structured regimen below.
DOI: 10.1016/j.jtha.2024.05.026
In individuals with severe hemophilia A with inhibitors who present with joint bleeding and will be treated with recombinant FVIIa (eptacog alfa), the ISTH Hemophilia Guideline Panel suggests treatment with either 3 doses of 90 μg/kg at 3-hour intervals or a single dose of 270 μg/kg (conditional recommendation, based on very low–certainty evidence ⨁◯◯◯).
View source ↗